Inositol is a cyclic sugar alcohol that is the structural basis for the phosphatidylinositol (PI) signaling pathway — one of the most important second messenger systems in human cells. When a hormone, neurotransmitter, or growth factor binds to its receptor on the cell surface, it activates an enzyme called phospholipase C, which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 then releases calcium from intracellular stores; DAG activates protein kinase C. This pathway is how dozens of different extracellular signals are translated into intracellular responses. Without adequate inositol to maintain the phosphatidylinositol pool, cellular signaling becomes impaired across multiple systems simultaneously.
Inositol and the Brain
In the brain, the phosphatidylinositol pathway is the primary signaling mechanism for at least three neurotransmitter systems: acetylcholine, norepinephrine, and serotonin (at certain serotonin receptors). This is why inositol has been studied as a treatment for depression, panic disorder, and OCD — conditions that are associated with dysregulation of these monoamine neurotransmitter systems. Inositol appears to work by optimising the efficiency of receptor-coupled phosphoinositide signaling, effectively amplifying the signal from a given amount of neurotransmitter.
Clinical trials of inositol in depression have shown modest but measurable benefits, with efficacy comparable to SSRIs in some studies but with a different side-effect profile. In panic disorder, inositol (18g daily) significantly reduced the frequency and severity of panic attacks compared to placebo in a double-blind crossover trial. In OCD, inositol (up to 18g daily) reduced Yale-Brown Obsessive Compulsive Scale scores by 30% or more in a substantial minority of treatment-resistant patients. The mechanism is consistent across all three conditions: optimised phosphoinositide signaling reduces the noise in the monoamine systems that are dysregulated in these conditions.
Inositol and Metabolic Health
In metabolic health, inositol — particularly the isomer myo-inositol — has emerged as a significant therapeutic agent for polycystic ovary syndrome (PCOS) and insulin resistance. In PCOS, inositol (typically as myo-inositol at 2-4g daily) improves insulin sensitivity, reduces hyperinsulinemia, normalises ovulation, and reduces androgen symptoms (hirsutism, acne). The mechanism involves inositol’s role as a second messenger for insulin itself: when insulin binds to its receptor, it activates phospholipase C, which requires phosphatidylinositol in the cell membrane to generate the IP3 and DAG second messengers. Without adequate inositol, insulin signaling is impaired at the second messenger step.
This is why inositol supplementation improves insulin sensitivity even in people who are not clinically deficient — the problem is not inositol deficiency per se, but the relative insufficiency of inositol relative to the demand created by chronic hyperinsulinemia. Correcting inositol status helps normalise the insulin signaling cascade. The combination of myo-inositol (4g daily) and D-chiro-inositol (a different inositol isomer, at 400mg daily) is the form that has shown the best results in PCOS studies — because it mirrors the natural ratio of these two inositols in the body.
Food Sources and Supplementation
Inositol is found in fruits, beans, grains, and nuts, but the amounts in a typical diet (approximately 1g daily) are well below the 4-18g doses used in clinical studies. Supplementing with myo-inositol powder at 2-4g daily is the evidence-based approach for PCOS and metabolic health applications. For mood and anxiety applications, higher doses of 12-18g daily are used — though GI tolerance (primarily loose stools) can be limiting at these doses.
The safety profile of inositol is excellent. It is a normal constituent of the diet and a normal metabolite in the body — no toxicity has been identified at any dose studied. The only caveat is that inositol should not be combined with serotonergic medications (SSRIs, MAOIs) without close monitoring, given the theoretical risk of serotonin syndrome from amplified serotonin signaling.
How GABA Works in the Nervous System
GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the mammalian central nervous system. Where glutamate promotes neuronal firing and excitation, GABA suppresses it — maintaining the balance between excitation and inhibition that allows the brain to function without constant seizure-like overactivation. GABAergic neurons make up approximately 20-30% of all neurons in the brain, and GABA receptors are present on virtually every neuronal type, making GABA the universal modulator of neural circuit activity. When GABA binds to GABA-A receptors, it opens chloride channels, hyperpolarising the neuron and making it less likely to fire. This is why GABA-promoting substances — whether pharmaceutical (benzodiazepines, barbiturates) or nutritional — tend to have calming, anxiolytic, and sometimes sedative effects.
The Gut-Brain GABA Axis
A substantial proportion of the body GABA is produced by gut bacteria, particularly Lactobacillus and Bifidobacterium species. These bacteria produce GABA via the glutamate decarboxylase pathway, and this GABA acts locally on the enteric nervous system, modulating gut motility, secretion, and pain signalling. There is bidirectional communication between gut-derived GABA and brain GABA function — the so-called gut-brain axis. Certain probiotic strains marketed as psychobiotics have been shown to increase GABA production and reduce anxiety behaviours in animal models, and preliminary human data suggests similar anxiolytic effects from specific multi-strain probiotics.
Why Oral GABA May Not Cross the Blood-Brain Barrier
A contentious area in nutritional neuroscience is whether orally consumed GABA can cross the blood-brain barrier. The evidence suggests that at typical supplemental doses (250-1000mg), systemic GABA does not meaningfully cross into the CNS. However, some studies show physiological effects from oral GABA — such as increased alpha brain wave activity on EEG and reduced cortisol — even if direct BBB penetration is minimal. Proposed mechanisms include vagal nerve activation from gut GABA receptors, or effects on peripheral GABA receptors that indirectly influence CNS function via neuroendocrine pathways.
A quality supplement routine can make a real difference to your results.
Leave a Reply